secwatch.observer — SEC 8-K summary
======================================

Issuer:     GERON CORP (GERN)
CIK:        0000886744
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0000950170-22-016865
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Geron Q2 net loss $28.1M; IMerge Phase 3 top-line results expected early Jan 2023
--------------------------------------------------------------------------------

- Net loss of $28.1M ($0.07 per share) vs $29.6M ($0.09) in Q2 2021; revenue $73K.
- Cash and marketable securities $220M as of June 30, 2022; debt facility expanded to $125M with $50M additional non-dilutive capital available in 2023.
- FY2022 GAAP operating expenses guided $155-165M; non-GAAP $140-150M.
- IMerge Phase 3 top-line results in lower risk MDS on track for early Jan 2023; U.S. NDA planned H1 2023, EU MAA H2 2023.
- Pipeline expansion: new studies in R/R AML and frontline MF starting H2 2022; IMpactMF interim analysis in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886744/000095017022016865/0000950170-22-016865-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886744/000095017022016865/gern-20220811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-016865

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer